More than 10 million people worldwide are living with Parkinson’s Disease (PD). Nearly 90,000 people are diagnosed in the US with PD each year. Although there is no cure for Parkinson’s disease, medicines, surgical treatment, and other therapies can often relieve some symptoms.
About Parkinson’s Disease
Parkinson’s Disease (PD) is a progressive brain disorder that affects the dopamine-producing neurons in a specific area of the brain called substantia nigra. Patients with PD suffer from movement-related symptoms such as tremor, slowness and freezing (bradykinesia and hypokinesia), stiffness, gait and balance issues. In addition, Parkinson’s symptoms may also be related to non-motor symptoms such as depression, anxiety, apathy, sleep disorders, and a variety of cognitive impairments. The progression of symptoms varies from person to person greatly.
Remepy’s hybrid drug for PD is a combination of Levodopa (L-Dopa) and a proprietary treatment protocol of digital interventions.
Reduce systemic and neuro-inflammation by influencing the HPA axis and sympathetic system and reducing pro-inflammatory cytokines.
Rebalance emotion and cognitive networks with psychological interventions focused on reducing stress, anxiety, depression, and developing resilience.
Address motor control with dedicated interventions focused on gait, movement, physiotherapy, speech therapy, and fine motor skills.
Improve brain plasticity in the within and between relevant networks, impacted by PD.
Gamification techniques maintain reward system health, harness the system to reinforce other activities, and to influence the immune system. Click here to learn more about the science behind hybrid drugs and the mechanisms of action.
Remepy’s hybrid drug for PD is a combination of Levodopa (L-Dopa) and a proprietary treatment protocol of digital interventions.
Reduce systemic and neuro-inflammation by influencing the HPA axis and sympathetic system and reducing pro-inflammatory cytokines.
Improve brain plasticity in the within and between relevant networks, impacted by PD.
Address motor control with dedicated interventions focused on gait, movement, physiotherapy, speech therapy, and fine motor skills.
Rebalance emotion and cognitive networks with psychological interventions focused on reducing stress, anxiety, depression, and developing resilience.
Gamification techniques maintain reward system health, harness the system to reinforce other activities, and to influence the immune system.
Click here to learn more about the science behind hybrid drugs and the mechanisms of action.
Parkinson’s Disease is a complicated neurodegenerative disease, and patients show a broad and diverse range of symptoms as the diseases progresses.
Remepy’s treatment protocol is adaptive and personalized, changing as the disease progresses, based on patient feedback and various metrics. Remepy’s hybrid drug leverages machine learning algorithms to adapt the treatment to the patient’s daily needs. Through the app, data is collected on patient progress, symptoms severity and frequency, and social schedule. Using AI, Remepy’s hybrid drug finetunes and recommends optimal dosage and timing. By optimizing dosage intake based on continuous data and patient feedback, ON/OFF times are optimized for better quality of life.
Remepy is currently conducting clinical trials for Parkinson’s Disease patients. If you are interested in learning more about our clinical trials, contact us today.
